BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), an organization digitizing biomarker evaluation to advance the science of precision well being, right now introduced that its ultra-sensitive Simoa expertise and varied blood-based neurology biomarker assays had been utilized by main analysis groups to energy 30 whole oral and poster displays at this 12 months’s AD/PD 2021. The analysis efforts additional underscore the huge utility of a number of blood-based biomarkers supplied by means of Quanterix’ Neurology kits, together with phosphorylated tau at threonine 181 (p-tau181), phosphorylated tau at threonine 231 (p-tau231), glial fibrillary acidic protein (GFAP) and Neurofilament mild chain (NfL). Notable findings showcased on the convention validate the potential of those markers as pre-screening instruments previous to expensive PET scans, as secondary endpoints of drug efficacy, and as vital instruments for the recruitment and illness stratification of pre-symptomatic sufferers into medical trials by means of non-invasive strategies.
“This 12 months’s AD/PD displays amplified the transformative potential of blood-based biomarkers to assist researchers advance therapies for Alzheimer’s and different neurodegenerative illnesses,” stated Chairman, Chief Govt Officer and President, Quanterix, and Founding father of Powering Precision Health (PPH), Kevin Hrusovsky. “The power to detect and quantify biomarkers indicative of cognitive efficiency non-invasively by means of the blood is game-changing for a lot of of our tutorial and business companions. They’re witnessing firsthand the potential to leverage these markers to see indicators of Alzheimer’s Illness (AD) previous to signs and enter sufferers into trials sooner, with out the necessity for expensive PET scans or spinal faucets. We additionally noticed an array of different functions made doable by Simoa’s extraordinarily excessive sensitivity and multiplexing capabilities, together with the event of strong blood biomarker panels to find out neurodegeneration early and discriminate between totally different types of cognitive impairment. We anticipate increasing our rising menu of blood primarily based neuro biomarkers for Alzheimer’s and Parkinson’s illness and really feel these advances signify an vital alternative for drug builders to extend their chance of getting an approval over the subsequent a number of years.”
Throughout this 12 months’s convention, researchers from establishments throughout the globe demonstrated the promise of Quanterix’ business main plasma biomarkers to help in screening, diagnosing and informing remedy for varied neurological situations. In a presentation entitled, “Blood Biomarkers For Alzheimer’s Illness – The Promise For Screening, Diagnostics And Remedy Monitoring,” Kaj Blennow, professor and chief doctor in Neurochemistry laboratory, Institute of Neuroscience and Physiology, Gothenburg College, demonstrated the power to harness blood biomarkers to precisely detect core AD pathologies, together with amyloid deposition, tau pathology and neurodegeneration, utilizing simply accessible blood checks. Blennow’s colleague, Henrick Zetterberg, professor and chief doctor, Institute of Neuroscience and Physiology, College of Gothenberg, additional explored the function of blood biomarkers in medical apply in his speak entitled, “Blood Biomarkers For Alzheimer’s Illness And Different Neurodegenerative Illnesses – Utility In Scientific Trials And Observe.”
Nicholas J. Ashton, assistant professor on the College of Gothenburg’s Division of Pyschiatry and Neurochemistry introduced one other notable paper, “Novel Plasma P-Tau231 In Alzheimer’ Illness: Early Enhance Signifies Utility For Preventive Trial Choice,” detailing the event and validation of a novel plasma p-tau231 assay utilizing Simoa assays for the preclinical evaluation of AD.
Further Simoa-powered papers highlighted the function of markers reminiscent of GFAP and NfL in neurogdegenerative illness analysis. These embrace two research from Andrea L. Benedet, postdoctoral researcher on the College of Gothenburg and Claudia Cicognola, assistant researcher at Scientific Reminiscence Analysis, Lund College, which examined GFAP’s utility as a biomarker for amyloid pathology within the AD spectrum and medical evolution to AD, respectively. Daniele D. Urso, medical analysis fellow at King’s Faculty London and the Parkinson’s Basis Centre of Excellence, King’s Faculty Hospital, London, additionally introduced findings that counsel serum NfL could possibly be utilized as a non-invasive medical marker for worsening non-motor signs (NMS) in Parkinson’s Illness (PD) development. Lastly, a number of displays demonstrated the function of blood primarily based biomarkers, reminiscent of NfL, as secondary endpoints in ongoing Alzheimer’s drug trials.
Hrusovsky hosted a panel dialogue highlighting extra insights from the AD/PD 2021 convention, with Dr. Andreas Jeromin, Unbiased Medical Advisor, Dr. Mark Roskey, SVP, Quanterix and Dr. Paula Perin, Principal Utility Scientist, Quanterix. The dialogue could be seen here. Hrusovsky additionally plans to current advances and host further panel discussions with business thought leaders in upcoming podcasts.
For a full checklist of Simoa-powered oral and poster displays, go to https://www.quanterix.com/conferences/15th-international-conference-on-parkinsons-and-alzheimers-diseases/.
To be taught extra about Quanterix’ expertise, go to https://www.quanterix.com/simoa-technology/.
Quanterix is an organization that’s digitizing biomarker evaluation with the objective of advancing the science of precision well being. The corporate’s digital well being answer, Simoa, has the potential to alter the best way by which healthcare is supplied right now by giving researchers the power to intently study the continuum from well being to illness. Quanterix’ expertise is designed to allow a lot earlier illness detection, higher prognoses and enhanced therapy strategies to enhance the standard of life and longevity of the inhabitants for generations to come back. The expertise is at present getting used for analysis functions in a number of therapeutic areas, together with oncology, neurology, cardiology, irritation and infectious illness. The corporate was established in 2007 and is situated in Billerica, Massachusetts. For extra info, please go to https://www.quanterix.com.
This press launch incorporates forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995. Phrases reminiscent of “might,” “will,” “count on,” “plan,” “anticipate,” “estimate,” “intend” and related expressions (in addition to different phrases or expressions referencing future occasions, situations or circumstances) are supposed to establish forward-looking statements. Ahead-looking statements on this information launch are primarily based on Quanterix’ expectations and assumptions as of the date of this press launch. Every of those forward-looking statements entails dangers and uncertainties. Components which will trigger Quanterix’ precise outcomes to vary from these expressed or implied within the forward-looking statements on this press launch are mentioned in Quanterix’ filings with the U.S. Securities and Trade Fee, together with the “Threat Components” sections contained therein. Besides as required by legislation, Quanterix assumes no obligation to replace any forward-looking statements contained herein to mirror any change in expectations, whilst new info turns into accessible.